Acadia shares plunge on report FDA is usually re-examining its drug

Acadia Pharmaceuticals shares plunged 22 percent Wednesday after a report the Food along with Drug Administration will re-examine its only drug.

Nuplazid, which treats hallucinations along with delusions coming from psychosis associated with Parkinson’s disease, has been scrutinized for reports of people dying while taking This specific. Lawmakers grilled Commissioner Scott Gottlieb in a hearing about why the agency approved the drug along with what This specific would likely take to have This specific removed coming from the market.

Gottlieb told members of Congress he would likely “take another look” at Nuplazid, CNN reports. The FDA told CNN This specific week This specific began conducting a brand new evaluation of the drug several weeks ago, before Gottlieb was questioned about This specific.

An FDA spokeswoman confirmed to CNBC the agency is usually conducting an evaluation of available information about Nuplazid.

The drug was first approved in 2016. Acadia did not immediately respond to CNBC’s request for comment.

Acadia’s stock has plummeted 56 percent over the past year.

Read the full CNN report here

Leave a Reply

Your email address will not be published. Required fields are marked *

*

sixteen + 12 =